GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
Rating: CLSN
Buy $9

CELSION CORP (NASDAQ: CLSN) rated to Buy with price target $9 by Maxim Group

Tuesday,  Jan 19, 2016  8:25 AM ET by Lynn Gilbert

Maxim Group rated CELSION
CORP (NASDAQ: CLSN) to Buy with price target $9.

Celsion Corporation (Celsion) is an oncology drug development company focused on developing drugs for the treatment of various cancer indications. The Company?s product ThermoDox is evaluated in a Phase III clinical trial for primary liver cancer and a Phase II study for recurrent chest wall breast cancer (RCW). ThermoDox is a liposomal encapsulation of doxorubicin, an oncology drug for the treatment of a range of cancers.

At Maxim Group, our vision for equity research is to be a client’s first call for value-added research on companies not widely followed by Wall Street. Maxim’s premier niche is emerging-growth companies in a variety of sectors, including healthcare, technology, retail and others. As strong believers in fundamental research, our analysts utilize a “bottom up” approach to making investment recommendations. We combine rigorous financial analysis of specific companies and industries with due diligence that includes frequent consults with suppliers, customers, competitors and senior management. By applying these skills and techniques, we are able to offer our clients differentiated research.



RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy